BMS-986120

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Healthy Adult VolunteersThrombosis

Phase 1

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

CompletedNCT02208882

Bristol-Myers SquibbHealthy Adult Volunteers

Start: 2014-08-31End: 2015-02-28Updated: 2015-07-07

CV004-007 Thrombosis Chamber Study

CompletedNCT02439190

Bristol-Myers SquibbThrombosis

Start: 2015-09-30End: 2016-03-31Updated: 2016-09-08

Related Papers

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

Platelets2022-06-2622 citations

PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation

Arteriosclerosis Thrombosis and Vascular Biology2017-12-21104 citations